Tikva attending MedInvest Biotech & Pharma Investor Conference in September

Tikva Allocell will be attending MedInvest Biotech & Pharma Investor Conference from September 18 to 19.

About Tikva Allocell

Tikva Allocell Pte Ltd is a late preclinical stage biotech company headquartered in Singapore. Our cell therapy platform is an off-the-shelf CAR-T therapy, utilizing highly specific second-generation allogeneic T cells prepared from the blood of Epstein-Barr virus (EBV)-positive healthy individuals. Our approach exploits the intrinsic properties of Virus-Specific T cells (VSTs), enhanced by IP-protected novel repurposing strategies to enhance cell performance and safely target patients with solid tumors including gastric, prostate and triple negative breast cancers.

For more information on Tikva, please visit www.tikvaallocell.com.

Investors and Media Contact

Wilson W. Cheung

FINANCIAL Advisor
Share the Post:

Related Posts

The multifarious role of SerpinB9 armoring

CAR-T cell therapy has revolutionized cancer treatment, but its efficacy against solid tumors remains limited due to challenges like poor CAR-T cell in-vivo survival. Tikva’s engineered SB9 EBVST platform will not only address a major resistance mechanism axis but also opens doors to more effective CAR T cell therapies for solid tumors.

Read More